Border Pediatrics in Derby Line, VT - Pediatrics

Border Pediatrics is a primary clinic (Pediatrics - Adolescent Medicine) in Derby Line, Vermont. The current practice location for Border Pediatrics is 159 Main St, Derby Line, Vermont. For appointments, you can reach them via phone at (802) 873-3009. The mailing address for Border Pediatrics is 159 Main St, Derby Line, Vermont and phone number is (802) 873-3009.

Border Pediatrics is licensed to practice in Vermont (license number 042-0008370) and its NPI number is 1750483780. This medical practice does not participate in medicare program and thus may not accept your medicare insurance. You may check if they accept your insurance at (802) 873-3009.

Contact Information

	Border Pediatrics
	159 Main St Derby Line VT 05830-8754
	(802) 873-3009
	(802) 873-3176

Primary Care Clinic Profile

Full Name	Border Pediatrics
Speciality	Pediatrics - Adolescent Medicine
Location	159 Main St, Derby Line, Vermont
Authorized Official Name and Position	Miriam Blodgett Tatum (PRESIDENT)
Authorized Official Contact	8028733009
Accepts Medicare Insurance	This clinic does not participate in Medicare Program.

Mailing Address and Practice Location

Mailing Address	Practice Location Address
Border Pediatrics 159 Main St Derby Line VT 05830-8754 Ph: (802) 873-3009	Border Pediatrics 159 Main St Derby Line VT 05830-8754 Ph: (802) 873-3009

NPI Details:

NPI Number	1750483780
Provider Enumeration Date	09/01/2006
Last Update Date	01/04/2013

Medical Identifiers

Medical identifiers for Border Pediatrics such as npi, medicare ID, medicare PIN, medicaid, etc.

Identifier	Type	State	Issuer
1750483780	NPI	-	NPPES

Medical Taxonomies and Licenses

Taxonomy	Type	License (State)	Status
207R00000X	Internal Medicine	042-0008363 (Vermont)	Secondary
2080A0000X	Pediatrics - Adolescent Medicine	042-0008370 (Vermont)	Primary

News Archive

Environmental factors may affect how infants' gut bacteria mature

Environmental factors like mode of delivery and duration of gestation may affect how infants' gut bacteria mature, and that rate could help predict later body fat, international researchers from the EpiGen consortium have found in collaboration with scientists at Nestlé Research Center in Switzerland.

Study: Cetuximab drug used in combination with chemotherapy to treat advanced colorectal cancer is not effective

Research from the University of Southampton has shown a drug, used in combination with chemotherapy to treat advanced colorectal cancer, is not effective in some settings, and indeed may result in more rapid cancer progression.

CHLA and Keck Medicine of USC develop new liquid biopsy for tumor of the retina

Retinoblastoma is a tumor of the retina that generally affects children under 5 years of age. If not diagnosed early, retinoblastoma may result in loss of one or both eyes and can be fatal. Unlike most cancers that are diagnosed using a biopsy, retinoblastoma tumors cannot be directly biopsied.

Caraco Pharmaceutical Laboratories begins marketing bupropion hydrochloride extended release tablets

Caraco Pharmaceutical Laboratories, Ltd. has started shipping bupropion hydrochloride extended release tablets. This product was recently approved by the US Food and Drug Administration (FDA) for Sun Pharma's Abbreviated New Drug Application (ANDA). These bupropion hydrochloride extended release tablets, 100 mg, 150 mg, and 200 mg, are therapeutically equivalent to GlaxoSmithKline's Wellbutrin SR® Extended Release tablets.

Border Pediatrics - Primary Care in Derby Line, VT